5月20日，药明合联盘中上涨3.17%，报56.9港元/股，成交额5503.44万港元。
消息面上，药明合联于5月18日公告，公司已议决动用最多1亿美元内部资金，委任专业受托人按当时市价在公开市场购买公司股份。公司明确表示，当前股份交易价格并未反映其内在价值或实际业务前景，认为此时进行回购系良机。董事会认为集团目前财务资源充裕，能以内部资源实施回购的同时维持稳固财务状况。此外，生物医药板块近期整体表现偏强，叠加回购利好持续发酵，推动股价延续上行。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.